





A NOVEL APPROACH TO TARGET INFLAMMATORY DISEASES

JOIN OUR SYMPOSIUM!

**OCTOBER 25TH, 2022 – 15:30
AMPHI HAVANE - CHANNEL N°3**

-  Targeting TREM-1 to Manage Life-threatening Immune Disorders Caused by Severe Infections
-  Application in Septic Shock and COVID-19

FIND US AT THE STAND: 4-22



TARGETING TREM-1 TO MANAGE LIFE-THREATENING IMMUNE DISORDERS CAUSED BY SEVERE INFECTIONS

APPLICATION IN SEPTIC SHOCK AND COVID-19

CHAIRS

- MARLIES OSTERMANN
CRITICAL CARE AND NEPHROLOGY,
Guy's and Saint Thomas Hospital, London, UK
- JÉRÔME PUGIN
INTENSIVE CARE UNIT,
University Hospital of Geneva, Switzerland

INOTREM

Inotrem is an advanced clinical stage biotechnology company specialized in immunotherapy. The company has developed a new concept of immunomodulation that targets TREM-1 to control unbalanced and dysregulated inflammatory responses.

RATIONALE FOR TARGETING THE TREM-1 PATHWAY IN SEPTIC SHOCK

From nangibotide discovery to a personalized medicine approach.

➤ **MARC DERIVE**
CHIEF SCIENTIFIC OFFICER
Inotrem, Nancy, France

ASTONISH

A phase IIb trial results in septic shock to open the way to a registration trial with a personalized medicine approach.


➤ **MITCHELL LEVY**
CHIEF, DIVISION OF PULMONARY AND CRITICAL CARE
DEPARTMENT OF MEDICINE,
The Warren Alpert Medical School of Brown University,
Providence, Rhode Island, USA

ESSENTIAL

A phase II randomized clinical trial in severe forms of COVID-19 to assess the efficacy and safety of nangibotide, and the potential predictive role of soluble TREM-1.

➤ **BRUNO FRANÇOIS**
MEDICAL - SURGICAL ICU & CLINICAL INVESTIGATION CENTER
Limoges University Hospital, France

FOLLOW OUR LIVE STREAMING ON WWW.ESICM.ORG



WWW.INOTREM.COM